Biotechnology News and Research

RSS

Wrapping in low molecular weight poly can help stabilize hemoglobin

A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, a discovery that could lead to the development of stable vaccines and affordable artificial blood substitutes.

4 Dec 2013

"Appearance exposure" on Internet linked to body image disturbance among adolescent girls

"Appearance exposure" on the Internet has been linked to body image disturbance among adolescent girls. A new study that links specific Facebook activities, but not overall Facebook use to body dissatisfaction and a drive for thinness in teen girls is published in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

4 Dec 2013

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

Frost & Sullivan released today its three big predictions for the global healthcare market. Based on a '2013 Search for Growth' survey which involved 1835 executives in more than 40 countries worldwide, Frost & Sullivan's insight highlights new areas of growth. mHealth, Cloud in Healthcare and Regulatory Environments will be the key subjects in 2014 and beyond.

4 Dec 2013

Life Technologies to support LabCentral-based startups conducting genetic and cellular analysis

LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences startups, announced that Life Technologies will provide an innovative technology suite of instruments representing the latest platforms developed by the company under an agreement inked last month.

4 Dec 2013

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Finnish healthcare company Biohit Oyj and American company Dynex Technologies, Inc. have signed an agreement for the distribution of the two-microplate DS2®, four-microplate DSX® and 12-microplate Agility® automated ELISA (enzyme-linked immunosorbent assay) processing systems, for use with the Biohit Oyj GastroPanel.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

NanoLogix, Inc. an innovator in the rapid detection, identification of live bacteria, and determination of their antibiotic resistance and sensitivity, announces that they are working with Nasaem-Aljazira, a Saudi Arabian company headquartered in Riyadh, to establish exclusive distribution and/or manufacturing of NanoLogix products in Saudi Arabia and the Arabian Gulf region, also known as the Gulf Cooperation Council (GCC) area.

4 Dec 2013

Rensselaer professors team up to develop innovative biomanufacturing technology

Two chemical engineering professors at Rensselaer Polytechnic Institute are contributing to a collaboration among academia, industry, and the federal government to develop a method for rapidly manufacturing biologic drugs.

4 Dec 2013

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.

3 Dec 2013

CUMC researchers make new breakthrough in regenerative medicine

As fast-growing biotech company Rainbow Coral Corp. works to deliver new cutting-edge treatments in the field of regenerative medicine, a major new breakthrough could soon lead to growing new lungs for patients in a laboratory.

3 Dec 2013

3T MRI scanner allows Polish scientists to perform structural and functional imaging of human brain

The Nencki Institute of Experimental Biology in Warsaw launches research programs, which require state-of-the-art magnetic resonance scanner.

3 Dec 2013

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Biogen Idec announced today that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application (BLA) for ALPROLIX, the company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.

2 Dec 2013

Xagenic announces closing of $20 million Series B financing

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the close of a Series B financing totaling $20 million. The round was led by new investor Domain Associates, LLC, which was joined by existing investors including CTI Life Sciences Fund and the Ontario Emerging Technologies Fund.

2 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Visterra, Inc., a developer of novel therapeutics to prevent and treat major infectious diseases, today announced that it has received $8.1 million in proceeds from an upsized and final closing of its Series A financing round. The company also announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, which follows the recent appointment of Brian Pereira, M.D. as President and Chief Executive Officer of Visterra this past summer.

2 Dec 2013

Pharmaceutical industry in Asia to experience intensified competition

As Asia emerges as a major engine of global economic growth, the pharmaceutical and biotechnology industries in the region are expected to experience intensified competition. According to the Economist Intelligence Unit, regional pharmaceutical sales are expected to hit USD386bn, reflecting an annual average growth rate of more than 13%.

2 Dec 2013

Scientists transform human stem cells into functional lung and airway cells

For the first time, scientists have succeeded in transforming human stem cells into functional lung and airway cells. The advance, reported by Columbia University Medical Center researchers, has significant potential for modeling lung disease, screening drugs, studying human lung development, and, ultimately, generating lung tissue for transplantation.

2 Dec 2013

European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

22nd Century Group, Inc. today announced that the European Patent Office issued a Notice of Grant to the company for the NBB and A622 genes. Both genes are responsible for nicotine production in the tobacco plant.

30 Nov 2013

Biotechnology News and Research

Wrapping in low molecular weight poly can help stabilize hemoglobin

"Appearance exposure" on Internet linked to body image disturbance among adolescent girls

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

Life Technologies to support LabCentral-based startups conducting genetic and cellular analysis

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

Rensselaer professors team up to develop innovative biomanufacturing technology

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

CUMC researchers make new breakthrough in regenerative medicine

3T MRI scanner allows Polish scientists to perform structural and functional imaging of human brain

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Xagenic announces closing of $20 million Series B financing

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

New biomarkers to improve diagnostics of prostate cancer

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Pharmaceutical industry in Asia to experience intensified competition

Scientists transform human stem cells into functional lung and airway cells

European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News